Diagnostic and prognostic markers in gliomas – an update

References

• Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175–90. PubMed PMID: 7977648. Pubmed Central PMCID: PMC1887413. eng.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473–9. PubMed PMID: 9776413. eng.
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852–61. PubMed PMID: 17047046. eng.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008;14:352–7. PubMed PMID: 19060598. eng.
   PubMedGoogle Scholar
• Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008;122:1778–86. PubMed PMID: 18076069. eng.
   PubMedGoogle Scholar
• Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098–104. PubMed PMID: 9329453. eng.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715–22. PubMed PMID: 16782911. eng.
   PubMed Web of Science ®Google Scholar
• Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831–6. PubMed PMID: 17515545. eng.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial9402. J Clin Oncol2006;24:2707–14. PubMed PMID: 16782910. eng.
   Google Scholar
• Kaloshi G, Everhard S, Laigle-Donadey F, et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 2008;70:590–5. PubMed PMID: 18285534. eng.
   PubMedGoogle Scholar
• Panageas KS, Iwamoto FM, Cloughesy TF, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol 2012;14:761–7. PubMed PMID: 22661585. Pubmed Central PMCID: PMC3367843. eng.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007;9:314–8. PubMed PMID: 17435180. Pubmed Central PMCID: PMC1907408. eng.
   PubMed Web of Science ®Google Scholar
• Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793–7. PubMed PMID: 10029064. eng.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003. PubMed PMID: 15758010. eng.
   PubMed Web of Science ®Google Scholar
• Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296–307. PubMed PMID: 15057289. eng.
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–4. PubMed PMID: 11070098. eng.
   PubMed Web of Science ®Google Scholar
• Everhard S, Kaloshi G, Crinière E, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740–3. PubMed PMID: 17192931. eng.
   PubMed Web of Science ®Google Scholar
• Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009;15:330–7. PubMed PMID: 19118062. eng.
   PubMed Web of Science ®Google Scholar
• Komine C, Watanabe T, Katayama Y, et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176–84. PubMed PMID: 12744471. eng.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96. PubMed PMID: 15758009. eng.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66. PubMed PMID: 19269895. eng.
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596–606. PubMed PMID: 17785346. eng.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12. PubMed PMID: 18772396. Pubmed Central PMCID: PMC2820389. eng.
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597–602. PubMed PMID: 18985363. eng.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73. PubMed PMID: 19228619. Pubmed Central PMCID: PMC2820383. eng.
   PubMed Web of Science ®Google Scholar
• von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011;21:74–87. PubMed PMID: 21129061. eng.
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261–5. PubMed PMID: 19359588. eng.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462: 739–44. PubMed PMID: 19935646. Pubmed Central PMCID: PMC2818760. eng.
   PubMed Web of Science ®Google Scholar
• Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601. PubMed PMID: 19798509. eng.
   PubMed Web of Science ®Google Scholar
• Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 2011; 121:241–52. PubMed PMID: 21069360. eng.
   PubMedGoogle Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150–4. PubMed PMID: 19636000. eng.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707–18. PubMed PMID: 21088844. eng.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16:1597–604. PubMed PMID: 20160062. eng.
   PubMed Web of Science ®Google Scholar
• Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792–5. PubMed PMID: 19933982. eng.
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560–6. PubMed PMID: 20975057. eng.
   PubMed Web of Science ®Google Scholar
• Labussière M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74: 1886–90. PubMed PMID: 20427748. eng.
   PubMed Web of Science ®Google Scholar
• Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010;70:8981–7. PubMed PMID: 21045145. eng.
   PubMed Web of Science ®Google Scholar
• Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118:1739–49. PubMed PMID: 18398503. Pubmed Central PMCID: PMC2289793. eng.
   PubMed Web of Science ®Google Scholar
• Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68: 8673–7. PubMed PMID: 18974108. Pubmed Central PMCID: PMC2577184. eng.
   PubMed Web of Science ®Google Scholar